Timothy Devos

List of Publications by Year in descending order

79 papers	1,918 citations	394421 19 h-index	265206 42 g-index
84 all docs	84 docs citations	84 times ranked	2528 citing authors

#	Article	IF	Citations
1	Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal, 2022, 59, 2101724.	6.7	38
2	Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19. JAMA Network Open, 2022, 5, e2147331.	5.9	38
3	Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis. Hematology, 2022, 27, 23-31.	1.5	6
4	Momelotinib reduces transfusion requirements in patients with myelofibrosis. Leukemia and Lymphoma, 2022, 63, 1718-1722.	1.3	8
5	Longâ€term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2â€year results from two pivotal phase 3 studies. European Journal of Haematology, 2022, 109, 205-214.	2.2	19
6	Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. Lancet Haematology,the, 2022, 9, e480-e492.	4.6	18
7	Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. Blood Advances, 2022, 6, 5171-5183.	5.2	12
8	Multipotent mesenchymal stromal cells in kidney transplant recipients: The next big thing?. Blood Reviews, 2021, 45, 100718.	5.7	7
9	Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide. Leukemia, 2021, 35, 1197-1202.	7.2	9
10	Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirusâ€2 (SARSâ€CoVâ€2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. British Journal of Haematology, 2021, 192, 1100-1105.	2.5	51
11	Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial. EBioMedicine, 2021, 66, 103288.	6.1	21
12	Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practiceâ€”data from a Belgian registry. Annals of Hematology, 2021, 100, 1723-1732.	1.8	15
13	Recanalization of portal axis after cavoportal hemitransposition in a liver transplant recipient with complete splanchnic thrombosis. Pediatric Transplantation, 2021, 25, e14097.	1.0	2
14	Improvement of transfusion practice and reduction in red blood cell utilization in Belgian hospitals: Results of a national survey and benchmarking. Vox Sanguinis, 2021, , .	1.5	0
15	Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly. Blood, 2021, 138, 2576-2576.	1.4	0
16	Predictors for Improvement in Patient-Reported Outcomes: Post-Hoc Analysis of a Phase 3 Randomized, Open-Label Study of Eculizumab and Ravulizumab in Complement Inhibitor-NaÃ¯ve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood, 2021, 138, 2196-2196.	1.4	4
17	Impact of bone marrow fibrosis grade in postâ€polycythemia vera and postâ€essential thrombocythemia myelofibrosis: A study of the MYSEC group. American Journal of Hematology, 2020, 95, E1-E3.	4.1	8
18	Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases. Microorganisms, 2020, 8, 1733.	3.6	16

#	Article	IF	Citations
19	One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naÃ¯ve to complement inhibitor therapy: open-label extension of a randomized study. Therapeutic Advances in Hematology, 2020, 11, 204062072096613.	2.5	24
20	A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials, 2020, 21, 981.	1.6	17
21	Long-Term Effect of Ruxolitinib (RUX) in Inadequately Controlled Polycythemia Vera (PV) without Splenomegaly: 5-Year Results from the Phase 3 Response-2 Study. Blood, 2020, 136, 40-41.	1.4	5
22	An International Multicentric Observational Study on the Use of Ruxolitinib in Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea: Results from Interim Analysis. Blood, 2020, 136, 8-10.	1.4	0
23	Risk Factors for Thrombotic Events in Patients with PNH: A Nested Case-Control Study in the International PNH Registry. Blood, 2020, 136, 6-8.	1.4	1
24	Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available. Leukemia and Lymphoma, 2019, 60, 3493-3502.	1.3	5
25	Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Medicine, 2019, 8, 4089-4092.	2.8	16
26	Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium. Acta Haematologica, 2019, 142, 197-207.	1.4	6
27	Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis. Annals of Hematology, 2019, 98, 1421-1426.	1.8	14
28	Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-NaÃ¯ve Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib. Blood, 2019, 134, 1663-1663.	1.4	5
29	Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry. Blood, 2019, 134, 4161-4161.	1.4	3
30	Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment NaÃ¯ve Myelofibrosis Patients. Blood, 2019, 134, 4164-4164.	1.4	21
31	Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group. Blood, 2019, 134, 2946-2946.	1.4	0
32	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica, 2018, 103, e392-e394.	3.5	31
33	Disease and treatment characteristics of polycythemia vera patients in Belgium: Results from a scientific survey. European Journal of Haematology, 2018, 100, 361-366.	2.2	5
34	Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. Leukemia Research, 2018, 69, 100-102.	0.8	13
35	Recommendations on the use of ruxolitinib for the treatment of myelofibrosis. Hematology, 2018, 23, 194-200.	1.5	2
36	Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer Journal, 2018, 8, 89.	6.2	13

#	Article	IF	Citations
37	Diagnosis and management of PNH: Review and recommendations from a Belgian expert panel. European Journal of Haematology, 2018, 101, 737-749.	2.2	27
38	Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Annals of Hematology, 2018, 97, 1591-1600.	1.8	53
39	Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients. Hematology, 2018, 23, 785-792.	1.5	23
40	Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available. Blood, 2018, 132, 1774-1774.	1.4	3
41	Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients in Real-World Clinical Practice: Data from a Belgian Registry. Blood, 2018, 132, 1744-1744.	1.4	3
42	Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly: 156-Week Follow-up from the Phase 3 Response-2 Study. Blood, 2018, 132, 1754-1754.	1.4	3
43	Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide. Blood, 2018, 132, 3037-3037.	1.4	0
44	Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients. Blood, 2018, 132, 3039-3039.	1.4	0
45	Diagnosing nocturnal paroxysmal hemoglobinuria: a singleâ€center 4â€year experience. International Journal of Laboratory Hematology, 2017, 39, 329-336.	1.3	4
46	Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncology, The, 2017, 18, 88-99.	10.7	205
47	A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia, 2017, 31, 2726-2731.	7.2	242
48	A haemovigilance team provides both significant financial and quality benefits in a University Hospital. Transfusion and Apheresis Science, 2017, 56, 199-205.	1.0	3
49	The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study. Clinical Biochemistry, 2017, 50, 452-454.	1.9	15
50	Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene. Haematologica, 2017, 102, 1605-1616.	3.5	29
51	Driver mutationsâ€™ effect in secondary myelofibrosis: an international multicenter study based on 781 patients. Leukemia, 2017, 31, 970-973.	7.2	41
52	SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitorâ€“NaÃ¯ve Patients With Myelofibrosis. Journal of Clinical Oncology, 2017, 35, 3844-3850.	1.6	243
53	A surprising cause of polycythaemia. Thorax, 2016, 71, 967-968.	5.6	1
54	Lack of clinical benefit of zoledronic acid in myelofibrosis: results of a prospective multi-center phase II trial. Leukemia and Lymphoma, 2016, 57, 470-473.	1.3	3

#	Article	IF	Citations
55	Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. Haematologica, 2015, 100, 893-897.	3.5	49
56	Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation: A Phase 1 Trial. Biology of Blood and Marrow Transplantation, 2015, 21, 720-728.	2.0	56
57	Myelofibrosis patients in Belgium: disease characteristics. Acta Clinica Belgica, 2015, 70, 105-111.	1.2	7
58	Demographics, Baseline Characteristics, and Disease Symptom Burden in RESPONSE-2: A Randomized, Phase 3 Study of Ruxolitinib in Polycythemia Vera Patients (pts) Who Are Resistant to or Intolerant of Hydroxyurea (HU). Blood, 2015, 126, 2807-2807.	1.4	2
59	MPL p.S204P Is a Recurrent Mutation in Essential Thrombocythemia. Blood, 2015, 126, 2837-2837.	1.4	1
60	Screening of <scp>JAK</scp>2 V617F and MPL W515 K/L negative essential thrombocythaemia patients for mutations in <scp>SESN</scp>2, <scp>DNAJC</scp>17, <scp>ST</scp>13, <scp>TOP</scp>1<scp>MT</scp>, and <scp>NTRK</scp>1. British Journal of Haematology, 2014, 165, 734-737.	2.5	5
61	Long-term follow-up in a patient with the dermato-neuro syndrome treated with high-dose melphalan, thalidomide, and intravenous immunoglobulins for more than 7Âyears. Annals of Hematology, 2014, 93, 1927-1928.	1.8	12
62	Post-cryopreservation viability of mesenchymal stem cells. Cytotherapy, 2014, 16, S83.	0.7	0
63	Bone healing with bortezomib-based regimens in multiple myeloma: a retrospective imaging study. International Journal of Hematologic Oncology, 2014, 3, 387-394.	1.6	2
64	Treatment with lenalidomide (RevlimidÂ®), cyclophosphamide (EndoxanÂ®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study. Acta Clinica Belgica, 2014, 69, 98-103.	1.2	10
65	Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients. Blood, 2014, 124, 1824-1824.	1.4	9
66	A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM). Blood, 2014, 124, 1826-1826.	1.4	4
67	Analysis of Genotype, Phenotype and Outcome in a Belgian Cohort of Essential Thrombocythemia. Blood, 2014, 124, 5584-5584.	1.4	0
68	JAK2 V617F-Negative and MPL W515K/L-Negative Essential Thrombocythemia: A High Resolution SNP Array Study. Blood, 2013, 122, 5258-5258.	1.4	0
69	Screening JAK2 V617F-Negative and MPL W515K/L-Negative Essential Thrombocythemia Patients For Mutations In SESN2, DNAJC17, ST13, TOP1MT, and NTRK1. Blood, 2013, 122, 5264-5264.	1.4	0
70	Subset characterization of myeloid-derived suppressor cells arising during induction of BM chimerism in mice. Bone Marrow Transplantation, 2012, 47, 985-992.	2.4	29
71	G-CSF stem cell mobilization in human donors induces polymorphonuclear and mononuclear myeloid-derived suppressor cells. Clinical Immunology, 2012, 143, 83-87.	3.2	95
72	KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia, 2009, 23, 492-500.	7.2	236

#	Article	IF	Citations
73	Late CD8+ T Cell-Dependent Xenoantibody Production in Innate Tolerant Nude Rats After Hamster Islet Grafting But Not After Hamster Heart Grafting. Transplantation, 2008, 85, 1489-1495.	1.0	4
74	Occurrence of Autoimmunity After Xenothymus Transplantation in T-Cell-Deficient Mice Depends on the Thymus Transplant Technique. Transplantation, 2008, 85, 640-644.	1.0	8
75	KIR-Ligand Incompatibility in the Graft-Versus-Host Direction Is Associated with Better Outcomes after Unrelated Cord Blood Stem Cell Transplantation for Acute Leukemia in Complete Remission. Blood, 2008, 112, 156-156.	1.4	1
76	Serial Serum Cytokine Measurement in a Patient with Systemic Scleromyxedema.. Blood, 2007, 110, 5100-5100.	1.4	0
77	Role of CD4+ and CD8+ T cells in the rejection of heart or islet xenografts in recipients with xenotolerance in the innate immune compartment. Transplantation Proceedings, 2005, 37, 516-517.	0.6	4
78	Pathogenesis of Autoimmunity After Xenogeneic Thymus Transplantation. Journal of Immunology, 2003, 170, 5936-5946.	0.8	14
79	Itraconazole for COVID-19: Preclinical Studies and a Proof-of-Concept Pilot Clinical Study. SSRN Electronic Journal, 0, , .	0.4	1